Last 461.95 INR
Change Today +6.95 / 1.53%
Volume 13.4K
HCBA On Other Exchanges
Symbol
Exchange
Mumbai
As of 6:27 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

novartis india ltd (HCBA) Snapshot

Open
463.00
Previous Close
455.00
Day High
464.00
Day Low
456.35
52 Week High
05/2/13 - 594.00
52 Week Low
09/3/13 - 361.00
Market Cap
14.8B
Average Volume 10 Days
10.2K
EPS TTM
37.46
Shares Outstanding
32.0M
EX-Date
07/16/13
P/E TM
12.3x
Dividend
10.00
Dividend Yield
2.16%
Current Stock Chart for NOVARTIS INDIA LTD (HCBA)

Related News

No related news articles were found.

novartis india ltd (HCBA) Related Businessweek News

No Related Businessweek News Found

novartis india ltd (HCBA) Details

Novartis India Limited engages in the manufacture and sale of healthcare products in India and internationally. It operates through four segments: Pharmaceuticals, Generics, Over-The-Counter, and Animal Health. The Pharmaceuticals segment offers a portfolio of prescription medicines in various therapeutic areas, including hypertension, metabolism, infectious diseases, neuroscience, oncology, ophthalmology, respiratory, rheumatology and auto-immunity, calcium supplementation, pain and inflammation, transplantation/immunology, central nervous system, and others through healthcare professionals primarily under the Esosteo, Macalvit Forte, Voveran, Lioresal, Sandimmun Neoral, and Tegrital brand names. This segment offers its products in various forms, such as tablets, capsules, liquid orals, injectables, creams and ointments, patches, and vials. The Generics segment offers retail generics products in various therapeutic areas, such as anti-TB, anti-DUB (gynecology), anti-histamines, antibiotics, anti-ulcerants, anti-diabetes, and cardiovascular. This segment offers its products in tablet and liquid-oral forms. The Over-The-Counter segment offers vitamins, minerals, and nutritional supplements, as well as products for the treatment of cough, cold, and allergy primarily under the Otrivin, Otrinoz, and T-minic brand names. It offers its products in various forms, which include powders-VMS, tablets, capsules, and liquid-orals. The Animal Health segment offers drug formulations and feed supplements in cattle and poultry markets under the Denagard, Mifex/Mifex Oral, Calborol, Protexin, Comshot, Oestrushot, and Panrely brand names. The company was founded in 1947 and is based in Mumbai, India. Novartis India Limited is a subsidiary of Novartis AG.

1,378 Employees
Last Reported Date: 05/14/13
Founded in 1947

novartis india ltd (HCBA) Top Compensated Officers

Vice Chairman, Managing Director and Member o...
Total Annual Compensation: 12.6M
Country Chief Financial Officer
Total Annual Compensation: --
Executive Officer
Total Annual Compensation: --
Executive Officer of OTC
Total Annual Compensation: --
Executive Officer of Pharmaceuticals
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

novartis india ltd (HCBA) Key Developments

Novartis India Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

Novartis India reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the company reported total income from operation (net) of INR 2,246.4 million compared to INR 2,338.0 million a year ago. Loss from operations before other income and finance costs was INR 15.5 million compared to profit from operations before other income and finance costs of INR 222.9 million a year ago. Profit from ordinary activates before tax was INR 215.6 million compared to INR 416.8 million a year ago. Net profit for the period was INR 152.3 million compared to INR 290.0 million a year ago. Basic and diluted earnings per share were INR 4.77 compared to INR 9.07 a year ago. The company reported net sales of INR 2,185.4 million for the quarter ended December, a fall of 4.3% year on year. For the nine months, the company reported total income from operation (net) of INR 6,616.6 million compared to INR 6,907.7 million a year ago. Loss from operations before other income and finance costs was INR 114.0 million compared to profit from operations before other income and finance costs of INR 789.4 million a year ago. Profit from ordinary activates before tax was INR 576.4 million compared to INR 1,396.6 million a year ago. Net profit for the period was INR 746.5 million compared to INR 953.2 million a year ago. Basic and diluted earnings per share were INR 23.36 compared to INR 29.82 a year ago.

Novartis Launches Voveran TPM gel in India

Phosphagenics Limited advised that Novartis has launched a topical diclofenac gel that has been formulated with Phosphagenics' proprietary TPM drug delivery system, under the product name 'Voveran TPM gel'. Voveran TPM gel is a prescription pharmaceutical product launched as a line extension to Novartis' Voveran brand (known as Voltaren in many geographic markets). Novartis will market the product which contains 1% diclofenac (w/w). Voveran TPM gel is a topical non-steroidal, anti-inflammatory drug indicated for the treatment of pain and inflammation of the muscles and joints caused by osteoarthritis, soft tissue rheumatism and injuries such as sprains and strains.

Novartis India Limited, Board Meeting, Jan 23, 2014

Novartis India Limited, Board Meeting, Jan 23, 2014. Agenda: To consider quarterly results.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HCBA:IN 461.95 INR +6.95

HCBA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HCBA.
View Industry Companies
 

Industry Analysis

HCBA

Industry Average

Valuation HCBA Industry Range
Price/Earnings 15.2x
Price/Sales 1.7x
Price/Book 1.6x
Price/Cash Flow 14.7x
TEV/Sales 1.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS INDIA LTD, please visit www.novartis.in/. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.